November 28, 2018 — The U.S. Food and Drug Administration today approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL) to be…Original Article
FDA Approves Truxima (rituximab-abbs), a Biosimilar to Rituxan for Non-Hodgkin’s Lymphoma
